Patents by Inventor Carlos Arrecubieta

Carlos Arrecubieta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS
    Publication number: 20160264650
    Abstract: The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 15, 2016
    Inventors: Anne Gurnett-Bander, Carlos Arrecubieta, Israel Lowy
  • Human antibodies to toxins
    Patent number: 9399674
    Abstract: The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: July 26, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Anne Gurnett-Bander, Carlos Arrecubieta, Israel Lowy
  • Human Antibodies to Clostridium difficile Toxins
    Publication number: 20130230531
    Abstract: The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Anne Gurnett-Bander, Carlos Arrecubieta, Israel Lowy
  • Inhibiting infections
    Patent number: 8389682
    Abstract: The invention relates to Staphylococcus epidermidis peptides, antibodies and nucleic acids that can inhibit Staphylococcus epidermidis infection of a mammalian subject and colonization of a medical device in the mammal.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: March 5, 2013
    Assignee: Trustees of Columbia University in the City of New York
    Inventors: Carlos Arrecubieta, Mei-Ho Lee, Franklin D. Lowy
  • INHIBITING STAPHYLOCOCCUS EPIDERMIDIS INFECTIONS
    Publication number: 20110117099
    Abstract: The invention relates to Staphylococcus epidermidis peptides, antibodies and nucleic acids that can inhibit Staphylococcus epidermidis infection of a mammalian subject and colonization of a medical device in the mammal.
    Type: Application
    Filed: January 16, 2008
    Publication date: May 19, 2011
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Carlos Arrecubieta, Mei-Ho Lee, Franklin D. Lowy